<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486499</url>
  </required_header>
  <id_info>
    <org_study_id>02-4407-V04</org_study_id>
    <nct_id>NCT00486499</nct_id>
  </id_info>
  <brief_title>I-125 Versus Pd-103 for Medium Risk Prostate Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Gregory Merrick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Theragenics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Puget Sound Health Care System</source>
  <brief_summary>
    <textblock>
      hypothesis: the shorter half-life of Pd-103 versus I-125, will increase the rate of tumor
      eradication.

      A total of 660 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 7
      to 9 and/or PSA 10–20 ng/ml) will be randomized to implantation with I-125 (144 Gy) versus
      Pd-103 (124 Gy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The objective of this study is test the hypothesis that the shorter half-life of
      Pd-103 versus I-125, will increase the rate of tumor eradication.

      Research plan:

      A total of 660 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 7
      to 9 and/or PSA 10–20 ng/ml) will be randomized to implantation with I-125 (144 Gy) versus
      Pd-103 (124 Gy).

      Methodology:

      Randomization will be accomplished by the method of random permuted blocks.

      Cancer status will be monitored by yearly serial serum PSA. Treatment-related morbidity will
      be monitored by personal interview, using standard American Urologic Association and
      Radiation Therapy Oncology Group criteria at 1, 3, 6, 12 and 24 months.

      Primary endpoint: Time to treatment failure. Patients with serum PSA above 0.5 ng/ml two
      years or more after treatment will be considered to have residual or recurrent cancer and to
      have failed therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA-based cancer eradication</measure>
  </primary_outcome>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>I-125 versus Pd-103 radioactive seed insertion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PSA 4-10 ng/ml

          -  Gleason score 5 or 6
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent E Wallner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound, Group Health Cooperative, U of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>kent E Wallner, md</last_name>
    <phone>206-768-5356</phone>
    <email>kent.wallner@med.va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Group Health Cooperative</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent E Wallner, MD</last_name>
      <phone>206-326-3490</phone>
      <email>kent.wallner@med.va.gov</email>
    </contact>
    <investigator>
      <last_name>Kent E Wallner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent E Wallner, MD</last_name>
      <phone>206-768-5356</phone>
      <email>kent.wallner@med.va.gov</email>
    </contact>
    <investigator>
      <last_name>Kent E Wallner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2007</study_first_submitted>
  <study_first_submitted_qc>June 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <last_update_submitted>June 12, 2007</last_update_submitted>
  <last_update_submitted_qc>June 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2007</last_update_posted>
  <keyword>radiation</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

